(S)-(+)-4-hydroxy-2,2-dimethyl-3-pentanone | 129215-75-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-(+)-4-hydroxy-2,2-dimethyl-3-pentanone
• 英文别名: (4S)-4-Hydroxy-2,2-dimethylpentan-3-one
• CAS: 129215-75-4
• 化学式: C₇H₁₄O₂
• 分子量: 130.187
• InChiKey: CLDPAGCOQSJLSP-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  叔丁基锂 、 (5S)-2,2,5-trimethyl-1,3-dioxolan-4-one 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.5h， 以17%的产率得到(S)-(+)-4-hydroxy-2,2-dimethyl-3-pentanone
  参考文献：
  名称：

  氧氮杂环丙烷化学。14. 使用对映体纯的（樟脑磺酰基）恶氮丙啶对酮烯醇化物进行不对称氧化

  摘要：

  Le mecanisme 通过 un etat de transition «ouvert» 遇到 en jeu une 取代 SN2 型 de l'anion enolate sur l'oxaziridine

  DOI：

  10.1021/ja00174a035

文献信息

• FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF
  申请人：SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

  公开号：US20160214994A1

  公开（公告）日：2016-07-28

  Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.

  揭示了一种融合嘧啶化合物，其中间体，制备方法以及其组成和应用。本发明提供了一种如式I所示的融合嘧啶化合物，该化合物的药用可接受盐，水合物，溶剂合物，以及光学异构体或前药。本发明还提供了应用式I所示的融合嘧啶化合物，药用可接受盐，水合物，溶剂合物，以及该化合物的光学异构体或前药在制备用于治疗和/或预防激酶相关疾病的药物中。本发明的融合嘧啶化合物I是一种高效的PI3激酶抑制剂，可用于制备用于预防和/或治疗细胞增殖性疾病，如癌症，感染，炎症和自身免疫疾病的药物。
• TRIAZOLE COMPOUNDS AS KSP INHIBITORS
  申请人：ABRAMS Tinya

  公开号：US20110256128A1

  公开（公告）日：2011-10-20

  The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.

  本发明提供了式I的三唑化合物，如本文所述。该发明还提供了一种包含式I化合物的治疗有效量的药物组合物，以及一种治疗哺乳动物患者中由KSP至少部分介导的疾病的方法，包括向需要此类治疗的哺乳动物患者施用式I化合物的治疗有效量。
• N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS
  申请人：Ewing R. William

  公开号：US20080045461A1

  公开（公告）日：2008-02-21

  The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that may stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

  本文所述主题提供了新颖的人类胰高血糖素样肽-1（GLP-1）受体调节剂，其生物活性类似或优于天然GLP-1肽，因此可用于治疗或预防与GLP活性相关的疾病或疾病。所述化合物包括化学修饰的肽，可以刺激2型糖尿病患者的胰岛素分泌，但也产生其他有益的胰岛素促分泌反应。这些合成肽GLP-1受体调节剂表现出对蛋白酶解的稳定性增加，使它们成为口服或静脉注射的理想治疗候选药物。所披露和声称的肽显示出理想的药代动力学特性和糖尿病疗效模型的理想效力。
• HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Ewing William R.

  公开号：US20080242593A1

  公开（公告）日：2008-10-02

  The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

  本发明提供了新型的人类胰高血糖素样肽-1（GLP-1）受体调节剂，其生物活性类似或优于天然GLP-1肽，因此可用于治疗或预防与GLP活性相关的疾病或障碍。此外，本发明提供了新型的化学修饰肽，不仅能刺激2型糖尿病患者的胰岛素分泌，还能产生其他有益的胰岛素促进反应。这些合成肽GLP-1受体调节剂具有较高的蛋白酶水解稳定性，使其成为口服或静脉注射的理想治疗候选药物。本发明的肽具有理想的药代动力学特性和糖尿病疗效模型的理想效力。
• N-terminally modified GLP-1 receptor modulators
  申请人：Ewing R. William

  公开号：US20070021346A1

  公开（公告）日：2007-01-25

  The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

  本文所描述的主题提供了一种新颖的人类胰高血糖素样肽-1（GLP-1）受体调节剂，其生物活性类似或优于天然GLP-1肽，因此可用于治疗或预防与GLP活性相关的疾病或障碍。所描述的化合物包括化学修饰的肽，不仅能够刺激II型糖尿病患者的胰岛素分泌，还产生其他有益的胰岛素促进反应。这些合成肽GLP-1受体调节剂表现出对蛋白酶水解的稳定性增加，使它们成为口服或静脉注射的理想治疗候选药物。所披露和要求的肽具有理想的药代动力学特性和糖尿病疗效模型中的理想效力。